ESR1 and breast cancer: Because BZA is already clinically approved for use in hormone replacement therapy and is a potent ERα antagonist in the breast, an agonist in bone, and neutral in the endometrium with long-term safety data in thousands of patients, we explored its ability to inhibit the Y537S and D538G ERα somatic mutants in breast cancer (Wardell et al., 2013a).